ReviewFrontiers in pharmacology2026
Medicinal plants as biological and socio-ecological components of One Health.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the World Health Organization (WHO) estimates that approximately 40% of contemporary pharmaceuticals are derived from natural products and traditional knowledge sources, medicinal and aromatic plants (MAPs) remain underrepresented in global health policy frameworks. While the One Health concept emphasizes the interdependence of human, animal, and environmental health, MAPs have historically been viewed mainly as passive resources rather than as dynamic biological and ecological actors. This review synthesizes interdisciplinary evidence published from 2015 to 2025 to reframe medicinal plants across the One Health continuum. By examining their potential role in antimicrobial resistance mitigation through phytochemical synergy, their contribution to ethnoveterinary practices that may support animal health management and zoonotic risk reduction, and their value as biotic indicators of ecosystem integrity, this study highlights how MAPs may help connect biodiversity conservation with global health security. The available evidence suggests that selected medicinal plants and plant-derived compounds may contribute to antimicrobial resistance mitigation through mechanisms such as biofilm inhibition, efflux pump suppression, and synergistic interactions with conventional antimicrobials. The review also highlights the growing vulnerability of medicinal plant resources to biodiversity loss, climate changes in secondary metabolite production, and the erosion of traditional knowledge systems. Based on these findings, we propose an integrated One Health framework for medicinal plants that supports transdisciplinary policies linking conservation biology with pharmaceutical and healthcare resilience. Recognizing medicinal plants as biological and socio-ecological mediators may strengthen efforts to address antimicrobial resistance, biodiversity loss, and emerging global health challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.